Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
Globe Newswire (Mon, 6-Apr 8:00 AM ET)
Business Wire (Fri, 20-Mar 7:42 PM ET)
Market Chameleon (Fri, 20-Mar 6:52 AM ET)
Business Wire (Fri, 20-Mar 9:09 AM ET)
Business Wire (Thu, 19-Mar 2:15 PM ET)
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Wed, 11-Mar 8:00 AM ET)
Globe Newswire (Thu, 5-Mar 8:00 AM ET)
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Globe Newswire (Mon, 23-Feb 8:00 AM ET)
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
Globe Newswire (Thu, 12-Feb 8:00 AM ET)
Globe Newswire (Mon, 9-Feb 8:00 AM ET)
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Verrica Pharmaceuticals trades on the NASDAQ stock market under the symbol VRCA.
As of April 8, 2026, VRCA stock price climbed to $6.05 with 26,565 million shares trading.
VRCA has a beta of 1.53, meaning it tends to be more sensitive to market movements. VRCA has a correlation of 0.05 to the broad based SPY ETF.
VRCA has a market cap of $103.93 million. This is considered a Micro Cap stock.
Last quarter Verrica Pharmaceuticals reported $5 million in Revenue and -$.51 earnings per share. This beat revenue expectation by $700,000 and exceeded earnings estimates by $.05.
In the last 3 years, VRCA traded as high as $114.10 and as low as $3.28.
The top ETF exchange traded funds that VRCA belongs to (by Net Assets): VXF, VTI, DFAS, AVTM.
VRCA has underperformed the market in the last year with a return of -6.3%, while the SPY ETF gained +35.3%. In the last 3 month period, VRCA fell short of the market, returning -25.5%, while SPY returned -1.9%. However, in the most recent 2 weeks VRCA has outperformed the stock market by returning +35.0%, while SPY returned +3.3%.
VRCA support price is $5.40 and resistance is $6.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRCA shares will trade within this expected range on the day.
